Lynch syndrome: from tumor testing to family prevention

1. A. MLH1/PMS2 deletion and duplication analysis (Why this does not fit)

   Structural MLH1/PMS2 defects could matter with a different protein pattern, but this tumor retains that pair.

   Reasoning steps for option A

   1. What does retained MLH1/PMS2 imply for MLH1/PMS2 deletion testing?

      This intact pair makes an MLH1/PMS2 structural defect a poor match for the tumor's MSH2/MSH6 loss.

   2. Which missing testing capability would this option supply?

      It would assess structural changes, but in the wrong protein pair for this pattern.

   3. Why does the prior negative coding panel not justify switching to MLH1/PMS2?

      Coding results leave structural variants unresolved; the absent MSH2/MSH6 pair still directs the structural search toward MSH2 and EPCAM.

2. B. MSH2 structural analysis and relevant EPCAM deletion testing (Best answer)

   Paired MSH2/MSH6 loss directs attention to MSH2 and EPCAM-related silencing. Structural testing addresses the limitation of the prior broad sequencing panel.

   Reasoning steps for option B

   1. How can an EPCAM deletion produce paired MSH2/MSH6 loss?

      A relevant EPCAM deletion can silence adjacent MSH2; loss of MSH2 destabilizes its partner MSH6.

   2. Which limitation of the prior blood panel does MSH2 structural analysis address?

      The panel checked coding sequence but did not assess deletions or duplications, so a constitutional MSH2 structural variant remains possible.

   3. Does paired tumor protein loss itself establish inherited MSH2 or EPCAM disease?

      No. It prioritizes appropriate constitutional structural testing, which is needed to establish an inherited cause.

3. C. MSH6-only deletion and duplication analysis (Why this does not fit)

   MSH6 is absent, but paired MSH2 loss points upstream; isolated MSH6 structural testing is too narrow.

   Reasoning steps for option C

   1. Why is isolated MSH6 structural testing too narrow when both MSH2 and MSH6 are absent?

      Loss of upstream MSH2 can secondarily eliminate MSH6 staining; an MSH2 or relevant EPCAM lesion remains unexamined.

   2. Which retained proteins distinguish this pattern from an MLH1-driven defect?

      MLH1 and PMS2 are retained, focusing the inherited investigation on the MSH2/MSH6 axis.

   3. What structural blind spot would MSH6-only analysis leave?

      It would not assess MSH2 deletions or relevant EPCAM deletions, despite the paired loss.

4. D. Repeat coding-sequence analysis of the four MMR genes (Why this does not fit)

   Repeating the already performed test category does not fill the unassessed structural-variant gap.

   Reasoning steps for option D

   1. What did the earlier blood panel already test?

      It assessed coding-sequence variants in all four mismatch-repair genes and found none.

   2. What untested variant class makes repeating that panel insufficient?

      Structural variants were not assessed, including MSH2 copy-number changes and relevant EPCAM deletions.

   3. How does the IHC pattern prioritize the missing assay?

      Absent MSH2/MSH6 with retained MLH1/PMS2 directs structural evaluation to the MSH2/EPCAM pathway rather than another coding-only round.

Takeaway: Use paired protein loss to select genetics evaluation, without treating the stain as a constitutional diagnosis.

Case sources: [1]

1. A. Acquired tumor MLH1 silencing (Best answer)

   Tumor methylation plus BRAF V600E and late onset without a concerning pedigree strongly favor acquired MLH1 silencing.

   Reasoning steps for option A

   1. What mechanism links MLH1 promoter methylation to paired MLH1/PMS2 loss?

      Tumor MLH1 silencing removes MLH1 and destabilizes its PMS2 partner.

   2. How does BRAF V600E refine the colorectal tumor interpretation?

      Together with MLH1 methylation, BRAF V600E supports a sporadic acquired MLH1-silenced pathway rather than a typical inherited MLH1 defect.

   3. Why is acquired silencing most likely rather than certain?

      Late presentation and an unremarkable pedigree reinforce the tumor markers, but these findings do not absolutely exclude inherited disease.

2. B. Constitutional pathogenic PMS2 variation (Why this does not fit)

   An isolated PMS2 defect is less consistent with paired loss plus direct evidence of MLH1 silencing.

   Reasoning steps for option B

   1. Would a primary PMS2 defect usually remove MLH1 staining as well?

      No. PMS2 loss from a PMS2 defect more often leaves MLH1 retained; this tumor loses both.

   2. Which direct tumor marker instead identifies an MLH1-centered mechanism?

      MLH1 promoter methylation supports silencing of MLH1 itself.

   3. How does BRAF V600E weigh against constitutional PMS2 variation here?

      In this colorectal tumor it further favors the acquired MLH1-silenced route over an inherited PMS2 explanation.

3. C. Constitutional pathogenic MLH1 variation (Why this does not fit)

   Inherited MLH1 disease can produce paired loss, but the combined reflex markers and clinical context favor an acquired explanation here.

   Reasoning steps for option C

   1. Can constitutional MLH1 variation produce the observed paired loss?

      Yes. A pathogenic MLH1 variant can lead to loss of both MLH1 and PMS2, so IHC alone cannot distinguish it.

   2. What findings make an acquired cause more likely in this case?

      Tumor MLH1 promoter methylation and BRAF V600E, alongside diagnosis at 76 without a suggestive pedigree, favor acquired silencing.

   3. Does BRAF V600E prove constitutional MLH1 variation impossible?

      No. The markers shift the likelihood; they are not a categorical exclusion of every inherited explanation.

4. D. Constitutional EPCAM deletion (Why this does not fit)

   EPCAM deletions typically affect MSH2 and would not be the leading explanation for this MLH1/PMS2 pattern.

   Reasoning steps for option D

   1. Which protein pathway is usually affected by an EPCAM deletion?

      A relevant EPCAM deletion can silence MSH2, commonly causing paired MSH2/MSH6 loss.

   2. How does this tumor's IHC differ from the EPCAM-associated pattern?

      It loses MLH1/PMS2, not MSH2/MSH6.

   3. What molecular evidence favors a different mechanism?

      Tumor MLH1 methylation with BRAF V600E points to acquired MLH1 silencing.

Takeaway: Age, pedigree and reflex results modify the interpretation of MLH1/PMS2 loss.

Case sources: [1]

1. A. EPCAM deletion/duplication testing (Why this does not fit)

   EPCAM alterations explain MSH2 silencing rather than this loss pattern.

   Reasoning steps for option A

   1. What protein loss would make EPCAM deletion testing mechanistically relevant?

      A relevant EPCAM deletion can silence MSH2 and produce MSH2/MSH6 loss, not the observed MLH1/PMS2 loss.

   2. What does retention of MSH2/MSH6 indicate for this option?

      That the protein pair typically implicated by EPCAM-mediated MSH2 silencing is intact.

   3. Which reflex assay instead probes the missing MLH1/PMS2 pair?

      Tumor MLH1 methylation testing asks whether acquired MLH1 silencing explains the endometrial IHC finding.

2. B. BRAF V600E mutation testing (Why this does not fit)

   The colorectal BRAF shortcut is not the recommended endometrial reflex pathway.

   Reasoning steps for option B

   1. Why should a colorectal BRAF reflex not be imported into this case?

      The primary is endometrial, for which MLH1 promoter methylation is the relevant reflex to MLH1/PMS2 loss.

   2. What does valid paired MLH1/PMS2 loss warrant testing directly?

      Whether the tumor has MLH1 promoter methylation that explains the loss.

   3. Would BRAF V600E testing settle whether endometrial MLH1 loss remains unexplained?

      No. It is not the recommended endometrial reflex discriminator here.

3. C. MLH1 methylation testing (Best answer)

   Endometrial MLH1 loss calls for methylation testing; unexplained loss then prompts germline evaluation.

   Reasoning steps for option C

   1. Which retained pair localizes the defect away from MSH2-directed reflex testing?

      MSH2 and MSH6 are retained while MLH1 and PMS2 are absent with intact internal controls.

   2. What finding would make this endometrial MLH1 loss explicable by an acquired mechanism?

      Tumor MLH1 promoter methylation can account for MLH1 silencing and secondary PMS2 loss.

   3. When does constitutional evaluation become especially pertinent after this reflex?

      If methylation does not explain the paired loss, inherited evaluation is warranted rather than assuming an acquired cause.

4. D. Germline MLH1 sequencing now (Why this does not fit)

   Germline evaluation follows unexplained loss; methylation reflex can first identify acquired silencing in this endometrial pathway.

   Reasoning steps for option D

   1. What question should be answered before proceeding directly to germline MLH1 sequencing?

      Whether tumor MLH1 promoter methylation explains the endometrial MLH1/PMS2 loss.

   2. Why does intact internal control staining matter?

      It supports that the tumor's paired protein absence is a real finding requiring appropriate reflex interpretation.

   3. When would germline evaluation follow this tumor reflex?

      If MLH1 methylation does not explain the loss, the persisting unexplained defect supports constitutional evaluation.

Takeaway: Use tumor site as well as IHC when choosing a reflex assay.

Case sources: [1] [2]

1. A. Mother: germline evaluation; daughter: target a presumed MSH6 variant now (Why this does not fit)

   The maternal investigation fits, but the protein stain has not identified a specific pathogenic familial variant for targeting.

   Reasoning steps for option A

   1. What does isolated MSH6 loss establish about the mother's evaluation?

      With valid controls, it warrants constitutional assessment of the MSH6-associated pathway, especially with her sister's colorectal cancer.

   2. Does an MSH6-negative stain identify the daughter's exact familial allele?

      No. Protein loss is a tumor phenotype, not identification of a specific inherited pathogenic variant.

   3. What must precede informative targeted testing of the daughter?

      Establish a pathogenic familial variant through evaluation of the affected mother; a presumed MSH6 target is not yet known.

2. B. Mother: MLH1 methylation; daughter: target only an established pathogenic familial variant (Why this does not fit)

   Deferring targeted testing until a familial variant exists is correct, but MLH1 methylation does not explain isolated MSH6 loss.

   Reasoning steps for option B

   1. Why is MLH1 methylation a mismatch for isolated MSH6 loss?

      Methylation of MLH1 explains MLH1/PMS2 loss, not a tumor retaining those proteins and losing only MSH6.

   2. Which part of this proposed daughter plan is appropriately conditional?

      Targeted predictive testing becomes informative only after a pathogenic familial variant has been established.

   3. What should replace methylation in the mother's branch?

      Germline evaluation prompted by valid isolated MSH6 loss and the relevant family history.

3. C. Mother: MLH1 methylation; daughter: target a presumed MSH6 variant now (Why this does not fit)

   Neither the MLH1 reflex pathway nor a presumed familial target follows from the isolated MSH6 result.

   Reasoning steps for option C

   1. Which two assumptions fail in the combined methylation and presumptive-target plan?

      The isolated MSH6 stain does not suggest MLH1 silencing and does not reveal a specific familial pathogenic allele.

   2. What IHC pattern would instead raise an MLH1 methylation reflex?

      Paired MLH1/PMS2 loss, rather than isolated MSH6 loss with intact controls.

   3. Why is targeting a presumed MSH6 variant in the healthy daughter premature?

      Without identification of a pathogenic variant in the family, there is no established allele for an informative targeted test.

4. D. Mother: germline evaluation; daughter: target only an established pathogenic familial variant (Best answer)

   The isolated-loss pathway requires constitutional evaluation; informative targeted testing for the adult daughter follows identification of a familial pathogenic variant.

   Reasoning steps for option D

   1. What finding directs the affected mother toward germline evaluation?

      Her endometrial tumor has valid isolated MSH6 loss, with a sister who had colorectal cancer at 52.

   2. Why should the daughter's predictive test await a molecular diagnosis?

      The stain identifies lost protein, not an inherited pathogenic variant; targeted testing requires an established familial allele.

   3. How does testing the affected person improve interpretation for her daughter?

      If a pathogenic familial variant is found, the daughter can be tested specifically for it; otherwise a presumed target cannot yield an informative familial result.

Takeaway: Isolated MSH6 loss in endometrial cancer deserves inherited evaluation.

Case sources: [1] [2]

1. A. Pseudogene-resolving PMS2 sequence analysis without copy-number testing (Why this does not fit)

   This would resolve sequence assignment but leave the explicitly unassessed structural variants unexplored.

   Reasoning steps for option A

   1. Which reported laboratory limitation would pseudogene-resolving sequencing fix?

      It could assign sequence variants in the PMS2 exons that the first panel could not distinguish confidently from homologous sequence.

   2. Which second reported limitation would remain?

      Copy-number changes were not assessed, and sequence analysis alone would still miss relevant PMS2 deletions or duplications.

   3. Why does isolated PMS2 loss make that remaining gap consequential?

      PMS2 is the leading target from the IHC pattern, so its structural variants must also be evaluated.

2. B. Pseudogene-resolving PMS2 sequencing plus deletion/duplication analysis (Best answer)

   Isolated PMS2 loss identifies the leading target; this combination addresses both ambiguous homologous sequence and missing structural analysis.

   Reasoning steps for option B

   1. Why is PMS2 the priority despite a negative blood panel?

      The tumor loses PMS2 alone, while MLH1, MSH2 and MSH6 remain, and the panel had unresolved PMS2 exons.

   2. What does pseudogene-resolving sequencing contribute?

      It distinguishes PMS2 sequence from homologous regions so ambiguous exons can be assessed reliably.

   3. Why add deletion/duplication analysis rather than stop at sequencing?

      The original assay did not assess copy-number changes, so both sequence ambiguity and structural blind spots need resolution.

3. C. PMS2 deletion/duplication analysis without resolving ambiguous sequence (Why this does not fit)

   This addresses structural variants but leaves the stated ambiguous PMS2 exons unresolved.

   Reasoning steps for option C

   1. What does PMS2 deletion/duplication testing address from the methods note?

      It assesses the copy-number changes absent from the prior panel.

   2. What does it fail to clarify in several PMS2 exons?

      It does not resolve sequence calls confounded by homologous sequence or the PMS2 pseudogene.

   3. Why are both assay capabilities needed for this tumor pattern?

      Isolated PMS2 loss makes PMS2 the primary target, and both ambiguous sequence and untested structural variation remain possible.

4. D. Comprehensive MLH1 sequencing plus deletion/duplication analysis (Why this does not fit)

   MLH1 can sometimes explain isolated PMS2 loss, but the direct PMS2 target has not yet been adequately assessed.

   Reasoning steps for option D

   1. Could MLH1 sometimes be relevant to isolated PMS2 loss?

      Yes, but retained MLH1 and isolated PMS2 loss prioritize a direct PMS2 investigation first.

   2. What explicit weaknesses of the prior panel would MLH1 testing leave unresolved?

      Ambiguous PMS2 exons and absent PMS2 copy-number assessment would remain unaddressed.

   3. Which PMS2 methods match those two weaknesses?

      Pseudogene-resolving sequence analysis and PMS2 deletion/duplication testing address the respective gaps.

Takeaway: A negative result is only as informative as the assay and question it addresses.

Case sources: [1]

1. A. Repeat IHC alone, then end testing if the proteins remain detectable (Why this does not fit)

   A protein can retain antigenicity despite impaired function; retained staining is not an absolute exclusion.

   Reasoning steps for option A

   1. Does detectable MMR protein staining prove mismatch repair is functional?

      No. An antigenically intact but dysfunctional protein may stain despite an MSI-high phenotype.

   2. Why is repeating only IHC inadequate after repeatedly MSI-high results?

      Even persistent staining would not explain the independent evidence of repeat-length instability.

   3. What further context makes ending assessment especially unsafe?

      Cancer at 38 and a father diagnosed at 42 support review of discordant tumor assays and inherited risk.

2. B. Treat MSI-high as a germline result and offer relatives targeted MLH1 testing (Why this does not fit)

   MSI-high does not identify the causal gene or establish inheritance.

   Reasoning steps for option B

   1. What does MSI-high establish, and what does it not identify?

      It establishes a tumor instability phenotype but neither a particular germline gene nor constitutional inheritance.

   2. Why is targeted MLH1 testing for relatives unsupported?

      All four proteins are retained and no familial pathogenic MLH1 variant has been identified.

   3. Which investigation should precede a familial predictive target?

      Review and reconcile the MSI/IHC discrepancy and assess germline risk in the affected patient.

3. C. Use the paternal diagnosis to set screening and leave assays unreconciled (Why this does not fit)

   Family age matters, but ignoring the unresolved tumor findings could miss a testable inherited cause.

   Reasoning steps for option C

   1. What risk information does the father's colorectal cancer at 42 provide?

      It strengthens concern for familial risk alongside the patient's colorectal cancer at 38.

   2. Why can family-history screening alone not settle this case?

      Repeated MSI-high with retained IHC is unresolved and may indicate a testable mismatch-repair defect.

   3. What should accompany history-based risk assessment?

      Pathology review of assays and controls plus genetics assessment to evaluate the discordance.

4. D. Review tumor assays and controls, confirm discordance and assess germline risk (Best answer)

   Pathology review and genetics can reconcile assay limitations, dysfunctional retained proteins and the suggestive pedigree.

   Reasoning steps for option D

   1. Which two different properties are measured by MSI testing and IHC?

      MSI measures repeat-length instability, whereas IHC measures detectable MMR protein expression.

   2. How might repeated MSI-high coexist with retained staining?

      A dysfunctional protein may retain its antigenic epitope, or assay and specimen issues may need review.

   3. Why include genetics assessment after confirming discordance?

      Early colorectal cancer in the patient and his father raises inherited concern, but neither assay alone establishes a germline diagnosis.

Takeaway: Discordance is a reason for review, not a reason to discard an abnormal result.

Case sources: [1]

1. A. Treat the defect as acquired and assess relatives by their own clinical history (Best answer)

   A tumor alteration plus loss of the other allele can explain biallelic inactivation without a constitutional cause; relatives do not have an established familial variant to target.

   Reasoning steps for option A

   1. How do the two tumor MSH2 events explain paired MSH2/MSH6 absence?

      A pathogenic tumor MSH2 alteration and loss of the other allele produce biallelic MSH2 inactivation, with secondary MSH6 loss.

   2. What does matched normal testing indicate about transmission?

      Neither alteration was detected constitutionally, so no transmissible familial MSH2 variant is established.

   3. On what basis should relatives be assessed instead?

      Use each relative's own clinical and family history rather than predictive testing for a tumor-only alteration.

2. B. Offer relatives predictive testing for the tumor MSH2 variant as a familial target (Why this does not fit)

   A tumor-only alteration is not an established transmissible familial variant.

   Reasoning steps for option B

   1. Why is the tumor MSH2 alteration not an established familial target?

      It was detected in the tumor but not in the matched normal sample.

   2. What additional tumor event explains the observed protein loss?

      Loss of the other MSH2 allele completes biallelic inactivation in the tumor.

   3. What would relatives need before targeted predictive testing could be informative?

      A demonstrated constitutional pathogenic familial variant, which the supplied testing has not found.

3. C. Assign each child a 50% variant risk and institute carrier surveillance (Why this does not fit)

   The 50% rule applies to constitutional heterozygosity, which has not been demonstrated here.

   Reasoning steps for option C

   1. When does a 50% transmission risk apply to children?

      It applies to a heterozygous constitutional pathogenic variant in a parent, not automatically to a tumor-only alteration.

   2. What do the paired tumor and normal specimens show here?

      MSH2 alteration and loss of the other allele are tumor-confined; matched normal testing does not show them.

   3. Why does this distinction change surveillance advice?

      Children cannot be assigned carrier status from acquired tumor events; assess their independent clinical and family risks.

4. D. Repeat MLH1 methylation testing to distinguish inherited from acquired MSH2 loss (Why this does not fit)

   MLH1 methylation does not explain this MSH2-associated pattern or resolve the already localized alterations.

   Reasoning steps for option D

   1. Which protein pair is absent in this endometrial tumor?

      MSH2 and MSH6, not MLH1 and PMS2.

   2. What does MLH1 methylation normally help explain?

      Tumor MLH1 silencing and consequent MLH1/PMS2 loss, which is not the observed mechanism.

   3. What existing result already explains the MSH2 loss?

      Tumor-confined pathogenic MSH2 alteration plus loss of the other allele supplies an acquired biallelic explanation.

Takeaway: An abnormal tumor and a negative germline result can be reconciled by double-somatic inactivation.

Case sources: [1]

1. A. Test relatives predictively for the uncertain MSH6 variant (Why this does not fit)

   Uncertain significance does not establish a disease-causing familial variant.

   Reasoning steps for option A

   1. What does uncertain significance say about the MSH6 variant's pathogenicity?

      Its disease-causing role is not established, so it cannot serve as a predictive familial pathogenic target.

   2. Why would testing relatives for that variant not determine carrier risk?

      A positive result would inherit the same uncertainty rather than prove Lynch syndrome.

   3. Whose testing has greater potential to clarify the family's cause?

      The father with colorectal cancer at 44 is alive and willing to undergo testing.

2. B. Apply pathogenic-MSH6 surveillance and surgical planning to the daughter (Why this does not fit)

   An uncertain variant is not equivalent to an established pathogenic MSH6 result for gene-specific prevention.

   Reasoning steps for option B

   1. What evidence is missing before applying pathogenic-MSH6 preventive measures?

      The daughter has only an MSH6 variant of uncertain significance, not a confirmed pathogenic familial variant.

   2. Why does the father's cancer not make the daughter's VUS pathogenic by itself?

      Early-onset family history raises risk but does not classify a particular uncertain allele as causal.

   3. How should her current screening risk be assessed?

      Use her family history while pursuing informative evaluation of the affected father, not automatic gene-specific surgery or surveillance based on the VUS.

3. C. Test the affected father and retain history-based screening for the daughter (Best answer)

   Testing the affected father may identify a familial cause. Until then, the daughter's uncertain result does not erase her early-onset family history.

   Reasoning steps for option C

   1. Why test the father rather than infer causation from the daughter's panel?

      He is affected and available, so testing him may identify a pathogenic familial cause that the unaffected daughter's uncertain result cannot establish.

   2. Does the daughter's VUS provide a true negative result for the family?

      No. No familial pathogenic variant is known, and a VUS is neither confirmation nor exclusion.

   3. What supports continued history-based screening for her?

      Her father's colorectal cancer at 44 remains relevant regardless of her uninformative panel finding.

4. D. Use population screening for the daughter because her panel found no pathogenic variant (Why this does not fit)

   An uninformative panel in this setting is not a true negative for a known familial cause.

   Reasoning steps for option D

   1. What makes a negative predictive test a true familial negative?

      A known familial pathogenic variant must be specifically excluded by an adequate test.

   2. Why does this daughter's broad panel fail that condition?

      No pathogenic familial cause has been identified, and her only finding is an uncertain MSH6 variant.

   3. Which fact prevents defaulting to population-risk screening now?

      Her father developed colorectal cancer at 44, so her risk assessment still depends on that family history.

Takeaway: Do not treat uncertainty as either pathogenicity or reassurance.

Case sources: [1]

1. A. Carrier: colonoscopy in the 20-to 25 window every 1 to 2 years; true negative: population screening (Best answer)

   The positive relative is in the MLH1 starting window; the adequate familial negative does not carry this identified risk.

   Reasoning steps for option A

   1. Why does the 23-year-old qualify for the MLH1 colonoscopy window?

      They carry their father's pathogenic MLH1 variant and are within the 20-to-25-year starting window, with surveillance every 1 to 2 years.

   2. Why is the 24-year-old not assigned the same carrier schedule?

      Adequate targeted testing excludes the known familial variant, and no independent risk is given.

   3. Does the father's diagnosis at 39 postpone the carrier's start?

      No. The MLH1 gene-specific start window applies even though the father's cancer was later.

2. B. Carrier: colonoscopy at 29 every 5 years; true negative: population screening (Why this does not fit)

   The carrier requires the earlier MLH1 framework rather than a generic ten-years-before-parent rule.

   Reasoning steps for option B

   1. What age would ten years before the father's diagnosis produce?

      It gives age 29, later than the MLH1 20-to-25-year starting window applicable to the carrier.

   2. What surveillance interval does the MLH1 carrier require instead of five years?

      The specified framework uses colonoscopy every 1 to 2 years.

   3. Which part of this paired option remains appropriate?

      Population screening fits the sibling with an adequate true negative and no independent risk.

3. C. Carrier: colonoscopy at 30 to 35 every 1 to 3 years; true negative: carrier screening (Why this does not fit)

   This assigns a later-gene schedule to MLH1 and incorrectly treats the negative sibling as a carrier.

   Reasoning steps for option C

   1. Why does a 30-to-35-year start misclassify this carrier?

      The pathogenic familial allele is MLH1, whose stated start window is 20 to 25 years, not a later-gene schedule.

   2. How does the 1-to-3-year interval compare with the specified MLH1 schedule?

      It is not the 1-to-2-year interval assigned to this MLH1 carrier under the stated framework.

   3. What does the adequate negative result mean for the other sibling?

      Without independent risks, the true negative should receive population rather than carrier screening.

4. D. Carrier: colonoscopy in the 20-to 25 window every 1 to 2 years; true negative: carrier screening (Why this does not fit)

   The carrier schedule fits, but the true negative does not require the same plan absent independent risk.

   Reasoning steps for option D

   1. Which half of this plan correctly addresses the variant-positive sibling?

      MLH1 carrier colonoscopy begins in the 20-to-25 window and repeats every 1 to 2 years.

   2. What distinguishes the variant-negative sibling from the carrier?

      The adequate targeted assay excluded the known paternal MLH1 pathogenic variant.

   3. Why is carrier surveillance for the true negative unjustified?

      They do not carry the identified familial risk and have no independent cancer risk, so population screening applies.

Takeaway: Gene-specific surveillance can begin well before the family's first observed cancer.

Case sources: [1]

1. A. Keep the order because the preceding colonoscopy was normal (Why this does not fit)

   The inherited result changes the appropriate interval despite the prior normal examination.

   Reasoning steps for option A

   1. Does a normal colonoscopy 12 months ago justify retaining the nine-year population order after PMS2 confirmation?

      No. The adequate examination counts, but the new pathogenic PMS2 result changes subsequent surveillance to a carrier interval.

   2. What interval replaces the scheduled nine-year wait?

      NCCN 2024 as summarized by NCI uses colonoscopy every 1 to 3 years for PMS2 carriers.

   3. What changed since the population-risk order was placed?

      A confirmed pathogenic PMS2 result now governs follow-up despite the normal colonoscopy.

2. B. Repeat at 40, then use 5-year intervals because family onset was late (Why this does not fit)

   Late family onset does not justify a population-like interval in a confirmed PMS2 carrier.

   Reasoning steps for option B

   1. Does the family's youngest colorectal cancer at 64 postpone this carrier's next colonoscopy until 40?

      No. Late family onset does not override the confirmed PMS2-associated surveillance schedule.

   2. Why are five-year repeats insufficient after age 40?

      A confirmed PMS2 carrier needs the cited 1-to 3-year interval, even after a normal examination.

   3. Does a late youngest family diagnosis cancel gene-based surveillance?

      No. Colorectal cancer at 64 does not justify delaying a known carrier to age 40.

3. C. Repeat within 1 to 3 years of the prior examination, then individualize (Best answer)

   Her prior examination occurred in the PMS2 starting window; she needs the 1-to 3-year carrier interval, not another 9-year wait.

   Reasoning steps for option C

   1. Can the high-quality colonoscopy at age 30 serve as the baseline examination?

      Yes. It occurred within the PMS2 starting window and need not be discarded merely because carrier status was confirmed later.

   2. When should surveillance resume after that normal examination?

      Repeat within 1 to 3 years of the examination, then individualize carrier surveillance rather than waiting nine years.

   3. Why is a fresh initiation date unnecessary?

      She already underwent a high-quality colonoscopy at 30, so the next decision concerns its carrier-based repeat interval.

4. D. Restart at 35, then use 5-year intervals because PMS2 has lower penetrance (Why this does not fit)

   PMS2 has later and lower colorectal risk than MLH1, but the cited repeat interval remains 1 to 3 years and a prior examination does not justify this prolonged gap.

   Reasoning steps for option D

   1. Does lower PMS2 penetrance require restarting screening at 35 despite an adequate examination at 30?

      No. The prior high-quality examination remains useful within the PMS2 starting window.

   2. Does a five-year interval follow from PMS2's later risk profile?

      No. The NCCN 2024 framework still calls for a 1-to 3-year repeat interval.

   3. How does the proposed age-35 restart affect the prior examination?

      It imposes an unnecessary gap after a valid examination rather than scheduling its next carrier-based repeat.

Takeaway: A later starting window is still an intensive surveillance plan.

Case sources: [1]

1. A. Start at 18, using the usual 10-year offset from the maternal diagnosis (Why this does not fit)

   This imports a generic 10-year family-history offset rather than the cited gene-specific early-onset rule.

   Reasoning steps for option A

   1. Is ten years before the mother's colorectal cancer at 28 the MSH6 early-onset rule?

      No. The cited gene-specific exception considers a start 2 to 5 years before the earliest family diagnosis when it occurred before 30.

   2. What age would the proposed ten-year subtraction produce?

      It produces 18, earlier than the 23-to 26 window derived from the applicable 2-to 5-year rule.

   3. Which relationship makes the age-28 diagnosis informative?

      Her mother carries the same MSH6 variant, directly linking the early cancer to this carrier family.

2. B. Plan initiation in the 23-to 26 window because of unusually early family onset (Best answer)

   Maternal CRC before 30 triggers consideration of a start 2 to 5 years earlier:28 minus 5 to 28 minus 2 gives 23 to 26. At 24 she is within that planning window.

   Reasoning steps for option B

   1. Does maternal colorectal cancer at 28 meet the early-family-onset threshold?

      Yes. It occurred before 30 in a relative carrying the same MSH6 variant.

   2. What initiation window follows from that diagnosis for this 24-year-old?

      Subtracting 5 to 2 years from 28 gives ages 23 to 26; she is already in that window.

   3. What practical consequence follows at her current age of 24?

      She should plan initiation now within the calculated 23-to 26-year window rather than defer to routine ages.

3. C. Wait until 30 to 35 because MSH6 always uses the later starting window (Why this does not fit)

   The usual later starting window can be modified by unusually early cancer in the family.

   Reasoning steps for option C

   1. Can the routine MSH6 starting window of 30 to 35 be used without modification here?

      No. A same-variant maternal colorectal cancer at 28 activates consideration of an earlier start.

   2. What does applying the family-history adjustment instead yield?

      A 2-to 5-year lead on age 28 yields an initiation window of 23 to 26, which includes her current age.

   3. Why is the age-30 threshold not absolute?

      The early-onset family exception modifies the usual MSH6 start when colorectal cancer occurs before 30.

4. D. Wait until 28 and repeat every 5 years because the family has only one cancer (Why this does not fit)

   The family-based start precedes the diagnosis, and a 5-year interval is longer than the cited carrier schedule.

   Reasoning steps for option D

   1. Should the carrier wait until the exact age of her mother's diagnosis?

      No. The early-onset exception considers colonoscopy 2 to 5 years before the maternal diagnosis at 28.

   2. Does having only one affected relative justify five-year colonoscopy intervals?

      No. The proposed five-year spacing is longer than the cited MSH6 carrier surveillance schedule.

   3. What does the proposed five-year interval confuse?

      A family-based adjustment to starting age does not convert carrier follow-up to five-year spacing.

Takeaway: Recognize when family timing modifies the usual gene-specific starting age.

Case sources: [1]

1. A. Repeat complete colonoscopy promptly with improved preparation, then use population intervals (Why this does not fit)

   The early repeat addresses inadequate visualization, but subsequent population intervals disregard MSH2-associated risk.

   Reasoning steps for option A

   1. What does prompt repeat with better preparation fix in today's examination?

      It allows assessment of the ascending colon obscured by solid stool despite washing.

   2. What is still wrong with population intervals after an adequate repeat?

      They ignore continuing MSH2-associated colorectal risk; short carrier intervals remain necessary.

   3. Does the high-quality examination 18 months earlier make today's blind spot acceptable?

      No. The adequate examination 18 months earlier does not establish what is present in the poorly visualized ascending colon today.

2. B. Accept this examination and wait another full 2-year carrier interval (Why this does not fit)

   The current examination is not adequate to assign a normal surveillance interval; the unseen proximal colon remains unevaluated.

   Reasoning steps for option B

   1. Can lesion-free visualized segments establish a negative whole-colon examination?

      No. Solid stool left the ascending colon inadequately examined.

   2. Why not wait another full two-year carrier cycle?

      An incomplete examination cannot reset the routine surveillance clock while proximal bowel remains unevaluated.

   3. Which immediate defect must be corrected before assigning a new interval?

      The solid stool obscuring the ascending colon requires a prompt adequate whole-colon repeat.

3. C. Repeat only the distal examination, then resume short-interval colonoscopy (Why this does not fit)

   Repeating distal visualization does not address the obscured ascending colon.

   Reasoning steps for option C

   1. Which segment was not adequately visualized today?

      The ascending colon, not the distal bowel, remained obscured despite washing.

   2. Why does repeating only the distal examination fail?

      It leaves the actual blind spot in the ascending colon unresolved; a complete colonoscopy with improved preparation is needed.

   3. Why is improved bowel preparation relevant to the repeat?

      It targets the solid-stool obstruction that prevented inspection of the ascending colon.

4. D. Repeat complete colonoscopy promptly with improved preparation, then retain carrier intervals (Best answer)

   First obtain an adequate whole-colon examination rather than waiting another routine cycle. Then use the short carrier interval; stool testing is not an equivalent replacement.

   Reasoning steps for option D

   1. What immediate action addresses the obscured ascending colon?

      Promptly repeat a complete colonoscopy with improved preparation instead of accepting the apparent negative examination.

   2. After an adequate examination, can annual stool testing or population spacing replace MSH2 surveillance?

      No. Maintain short MSH2 carrier colonoscopy intervals; stool testing is not an equivalent replacement.

   3. What does a negative view of the segments seen today actually establish?

      Only those visualized segments had no lesions; the ascending colon still requires adequate examination.

Takeaway: A reassuring examination changes findings, not the inherited predisposition.

Case sources: [1] [8]

1. A. Less colon at risk; no rectal surveillance; possible increased stool frequency (Why this does not fit)

   Retaining rectum preserves a site at risk, so surveillance remains necessary despite the reduced colonic burden.

   Reasoning steps for option A

   1. Does ileorectal anastomosis remove the rectum?

      No. Subtotal colectomy leaves rectal tissue susceptible to subsequent cancer.

   2. Which prediction fails despite reduced colon and possibly more frequent stools?

      Eliminating rectal surveillance is incorrect because retained rectum still needs surveillance.

   3. Does removing more colon remove every colorectal cancer surveillance target?

      No. The rectum retained for ileorectal anastomosis remains a surveillance target.

2. B. Less colon at risk; continued rectal surveillance; possible increased stool frequency (Best answer)

   The operation reduces susceptible colon but leaves rectum and can increase stool frequency; these separate outcomes inform the shared decision.

   Reasoning steps for option B

   1. How does removing most of the colon affect future colonic cancer risk?

      Less susceptible colon remains, reducing future colonic risk relative to right hemicolectomy.

   2. What two consequences remain after ileorectal anastomosis?

      The retained rectum requires surveillance, and diminished colonic reservoir can increase stool frequency.

   3. Why is this a functional tradeoff rather than an unqualified benefit?

      Reducing colon at risk can come with more frequent stools after extensive resection.

3. C. Less colon at risk; continued rectal surveillance; predictably reduced stool frequency (Why this does not fit)

   Retained rectal surveillance and colonic risk reduction fit, but subtotal colectomy is not expected to predictably reduce stool frequency.

   Reasoning steps for option C

   1. Which proposed effects of subtotal colectomy are accurate?

      It reduces colon at risk but retains a rectum requiring surveillance.

   2. Is stool frequency predictably lower after removal of most of the colon?

      No. Loss of colonic capacity may increase rather than reliably decrease stool frequency.

   3. What functional prediction better fits reduced colonic length?

      Possible increased stool frequency, not a predictable reduction.

4. D. Comparable colonic risk; continued rectal surveillance; possible increased stool frequency (Why this does not fit)

   Function and rectal surveillance fit, but leaving less colon reduces future colonic cancer risk rather than preserving an equivalent metachronous risk.

   Reasoning steps for option D

   1. Are stool-frequency increase and rectal surveillance plausible after subtotal colectomy?

      Yes. Bowel function may change, and the retained rectum remains at risk.

   2. Is future colonic risk comparable when far less colon remains?

      No. Removing more susceptible colon reduces metachronous colonic cancer risk relative to segmental resection.

   3. What surgical comparison makes the risk claim wrong?

      Subtotal colectomy leaves less colon at risk than a right hemicolectomy.

Takeaway: Cancer surgery balances future organ risk against current functional costs.

Case sources: [1]

1. A. A: Lynch-specific remnant-colon surveillance;B: Lynch-specific remnant-colon surveillance (Why this does not fit)

   A needs inherited-risk surveillance, but B's well-supported acquired pathway does not establish the same inherited indication.

   Reasoning steps for option A

   1. Why does patient A need Lynch-specific surveillance of remaining colon?

      A has a constitutional pathogenic MLH1 variant and retains colon after segmental surgery.

   2. Does patient B's MLH1/PMS2 loss alone establish the same inherited indication?

      No. Tumor methylation, BRAF V600E, negative genetics evaluation and an unremarkable pedigree support acquired silencing; B still needs standard post-cancer endoscopy.

   3. Which finding makes the patients unlike despite identical deficient IHC proteins?

      Only A has a confirmed constitutional MLH1 variant; B has evidence for acquired tumor MLH1 silencing.

2. B. A: standard post-cancer surveillance alone;B: Lynch-specific remnant-colon surveillance (Why this does not fit)

   This reverses the constitutional and acquired implications of the supplied results.

   Reasoning steps for option B

   1. Which patient has a confirmed constitutional MLH1 predisposition?

      Patient A, not B, has a pathogenic germline MLH1 variant.

   2. Why is assigning Lynch-specific follow-up to B but standard follow-up to A reversed?

      B's reflex results support acquired MLH1 silencing, while A's inherited risk persists in the remaining colon.

   3. Does B’s prior cancer remove the need for endoscopic follow-up?

      No. The correct distinction is standard post-cancer surveillance rather than no surveillance.

3. C. A: Lynch-specific remnant-colon surveillance;B: standard post-cancer surveillance (Best answer)

   A's constitutional predisposition determines intensive retained-colon surveillance. B still needs post-cancer endoscopy but does not have an established Lynch-specific indication.

   Reasoning steps for option C

   1. What distinguishes A's retained-colon risk after segmental colectomy?

      A's constitutional MLH1 variant warrants Lynch-specific remnant-colon surveillance despite normal current examinations.

   2. What endoscopy does B still need without established Lynch syndrome?

      Standard post-cancer surveillance remains indicated; supported acquired MLH1 silencing does not itself impose Lynch-specific intervals.

   3. Do normal remnant-colon examinations remove either patient’s future follow-up?

      No. A retains inherited-risk surveillance and B retains standard post-cancer surveillance.

4. D. A: standard post-cancer surveillance alone;B: standard post-cancer surveillance (Why this does not fit)

   B's standard post-cancer plan fits, but A's confirmed MLH1 predisposition requires its additional inherited-risk framework.

   Reasoning steps for option D

   1. Is standard post-cancer surveillance suitable for B?

      Yes. B still requires post-cancer endoscopy despite evidence favoring an acquired tumor pathway.

   2. Why is that standard schedule alone insufficient for A?

      A has confirmed constitutional MLH1-associated risk in the retained colon and needs Lynch-specific surveillance.

   3. Does A’s age of 68 alone negate inherited-risk follow-up?

      No. The stem specifies adequate life expectancy and fitness for ongoing endoscopy.

Takeaway: Constitutional risk modifies retained-colon surveillance; an acquired tumor pathway does not erase post-cancer follow-up.

Case sources: [1]

1. A. A: hysterectomy alone under the PMS2 exception;B: consider hysterectomy alone (Why this does not fit)

   B's option fits, but the PMS2-specific exception cannot simply be assigned to A's MSH2 risk profile.

   Reasoning steps for option A

   1. Can A's MSH2 variant be managed using the PMS2-only hysterectomy exception?

      No. The NICE exception for hysterectomy alone in this setting concerns the heterozygous PMS2 profile, not A's MSH2 profile.

   2. Which part of this pairing remains appropriate for B?

      At 46 with heterozygous PMS2 and no ovarian cancer family history, B can consider hysterectomy alone after childbearing.

   3. What gene difference prevents applying B’s exception to A?

      A carries MSH2, whereas the hysterectomy-alone exception described here concerns heterozygous PMS2.

2. B. A: defer endometrial prevention and discuss ovarian surgery alone;B: consider hysterectomy alone (Why this does not fit)

   Ovarian surgery alone does not address A's endometrial risk-reduction goal after childbearing.

   Reasoning steps for option B

   1. Does ovarian surgery alone address A's endometrial risk-reduction goal?

      No. A's uterus would remain; MSH2 supports discussing hysterectomy with bilateral salpingo-oophorectomy.

   2. Is the proposed hysterectomy-alone discussion for B the error?

      No. B meets the PMS2-specific conditions for considering that option; the mismatch is A's ovarian-only plan.

   3. Which organ remains exposed if A has ovarian surgery without hysterectomy?

      Her uterus remains, leaving the endometrial risk that the proposed risk-reduction discussion must address.

3. C. A: discuss hysterectomy with bilateral salpingo-oophorectomy;B: require the identical combined operation (Why this does not fit)

   The discussion for A fits the named framework, but it does not make combined surgery mandatory for B.

   Reasoning steps for option C

   1. Is combined hysterectomy and bilateral salpingo-oophorectomy appropriate to discuss with A?

      Yes. A's MSH2 status and completed childbearing make the combined risk-reduction discussion pertinent.

   2. Must B undergo the identical combined operation?

      No. At 46 with heterozygous PMS2 and no ovarian cancer family history, NICE permits consideration of hysterectomy alone.

   3. Which patient’s ovarian operation must not be made mandatory by analogy?

      B’s: heterozygous PMS2 status without ovarian cancer family history permits hysterectomy-alone consideration.

4. D. A: discuss hysterectomy with bilateral salpingo-oophorectomy;B: consider hysterectomy alone (Best answer)

   NICE distinguishes MSH2-associated combined risk-reduction discussion from consideration of hysterectomy alone in this PMS2 setting; individual counseling remains essential.

   Reasoning steps for option D

   1. What operation should be discussed for A's MSH2-associated gynecologic risks?

      Discuss hysterectomy with bilateral salpingo-oophorectomy, including the surgical and menopause consequences.

   2. What distinction allows B a different discussion at age 46?

      For a heterozygous PMS2 carrier without ovarian cancer family history, NICE allows consideration of hysterectomy alone; ovarian surgery is individualized.

   3. Why do the distinct discussions not eliminate shared counseling?

      Both patients still need consent, surgical-risk and menopause counseling before individualized decisions.

Takeaway: A shared syndrome label does not make uterine and ovarian surgical decisions identical across genes.

Case sources: [1] [4] [5]

1. A. Consider hysterectomy alone now; individualize additional ovarian surgery (Best answer)

   NICE permits hysterectomy alone from 45 in this PMS2 context; adding ovarian surgery depends on history, age and menopause.

   Reasoning steps for option A

   1. Does this carrier meet the age and gene conditions for the NICE hysterectomy-alone option?

      Yes. She is 46, heterozygous for PMS2, has completed childbearing and has no ovarian cancer family history.

   2. Is removal of the ovaries automatically required with hysterectomy?

      No. Hysterectomy alone can be considered from 45 in this PMS2 setting; ovarian surgery requires individualized counseling about risk and menopause.

   3. What is the purpose of the hysterectomy discussion in this question?

      To reduce endometrial risk after childbearing, without automatically committing her to ovarian removal.

2. B. Offer combined hysterectomy and ovarian surgery as the only gene-appropriate option (Why this does not fit)

   The named NICE framework permits consideration of hysterectomy alone in this PMS2 context; combined surgery is not the only gene-appropriate option.

   Reasoning steps for option B

   1. What makes combined surgery an unnecessarily exclusive recommendation here?

      NICE permits consideration of hysterectomy alone from age 45 for this heterozygous PMS2 carrier without ovarian cancer family history.

   2. What remains to discuss if ovarian surgery is contemplated?

      Ovarian risk, family history, age and the consequences of premenopausal oophorectomy should inform that separate decision.

   3. Which missing risk factor weakens the claim that ovarian surgery is obligatory?

      She reports no ovarian cancer family history, supporting individualized rather than compulsory ovarian surgery.

3. C. Require deferring hysterectomy until natural menopause (Why this does not fit)

   At 46 she is within the NICE age framework for considering hysterectomy alone. Waiting for natural menopause is not a prerequisite for that discussion; ovarian surgery is a separate decision.

   Reasoning steps for option C

   1. Must a 46-year-old PMS2 carrier await natural menopause before discussing hysterectomy?

      No. She has completed childbearing and already meets the NICE age threshold of 45 for considering hysterectomy alone.

   2. Why might menopause still matter to surgical counseling?

      Additional ovarian surgery could cause surgical menopause, but menopause is not a prerequisite to discussing uterine risk reduction.

   3. Which timing threshold does the proposed delay ignore?

      NICE permits considering hysterectomy alone from age 45 in this PMS2 setting; she is 46.

4. D. Offer ovarian surgery alone now and rely on surveillance for endometrial prevention (Why this does not fit)

   The stated aim is endometrial prevention. Ovarian surgery alone does not accomplish it, and endometrial screening has no established equivalent preventive benefit.

   Reasoning steps for option D

   1. Would ovarian surgery alone remove the source of endometrial risk?

      No. The uterus remains, so it fails her stated endometrial prevention objective.

   2. Can endometrial surveillance substitute for a proven preventive operation in this proposal?

      No. Screening has no established equivalent preventive benefit, while hysterectomy alone is a permissible discussion for her PMS2 profile.

   3. Why does the option misalign the operation with her stated goal?

      It removes ovaries but leaves the endometrium in place despite her endometrial risk-reduction aim.

Takeaway: Use gene-specific ovarian counseling rather than a single operation for every carrier.

Case sources: [5]

1. A. Repeat ultrasound in 6 weeks and sample only if the stripe thickens (Why this does not fit)

   A thin stripe does not provide sufficient reassurance to postpone tissue assessment in this symptomatic high-risk patient.

   Reasoning steps for option A

   1. Does a 3 mm stripe exclude the need for tissue evaluation of new bleeding in this MSH6 carrier?

      No. A thin ultrasound stripe alone is insufficient reassurance for this symptomatic high-risk patient.

   2. Why not postpone sampling until a thicker stripe appears in six weeks?

      The new postmenopausal bleeding poses a current diagnostic question that requires tissue assessment rather than conditional ultrasound follow-up.

   3. What feature changes this from routine surveillance to diagnostic assessment?

      She now has postmenopausal bleeding, a new symptom arising after her prior benign sample.

2. B. Obtain endometrial tissue as part of the current diagnostic evaluation (Best answer)

   Her prior surveillance sample predates the new symptom. ACOG's 2026 update favors ultrasound plus tissue sampling for most postmenopausal bleeding evaluations, especially when risk makes ultrasound-only reassurance inappropriate.

   Reasoning steps for option B

   1. Does the benign biopsy eight months before bleeding assess this episode?

      No. It predates the new symptom and cannot rule out pathology causing current postmenopausal bleeding.

   2. What should be obtained despite an adequately measured 3 mm stripe?

      Endometrial tissue during the current diagnostic evaluation; ultrasound alone does not settle this high-risk presentation.

   3. What specifically is absent from the current episode’s workup?

      No endometrial tissue has been obtained since this bleeding began.

3. C. Treat presumed atrophic bleeding first and sample only if treatment fails (Why this does not fit)

   Atrophy can cause bleeding, but presuming it before appropriate evaluation risks missing endometrial pathology in this carrier.

   Reasoning steps for option C

   1. Can atrophy be assumed as the cause before assessing the endometrium?

      No. Although atrophy can cause bleeding, MSH6-associated risk makes endometrial pathology important to exclude.

   2. What is the danger of sampling only if empiric treatment fails?

      It delays tissue diagnosis of a potentially consequential cause of new postmenopausal bleeding.

   3. Does an ultrasound finding establish atrophy as the cause?

      No. A 3 mm stripe does not diagnose the source of bleeding or exclude a lesion needing tissue assessment in this setting.

4. D. Wait for the next scheduled surveillance biopsy because the stripe is thin (Why this does not fit)

   A surveillance calendar and a thin stripe do not settle a new diagnostic problem; tissue from eight months earlier does not assess this episode.

   Reasoning steps for option D

   1. Does the next surveillance biopsy replace evaluation of this new symptom?

      No. Scheduled surveillance is different from diagnostic assessment of current postmenopausal bleeding.

   2. Why do the prior benign biopsy and thin stripe not justify waiting?

      The biopsy preceded the episode and a 3 mm stripe alone does not adequately resolve the present high-risk diagnostic question.

   3. What temporal limitation applies to the benign biopsy?

      It was taken eight months before the new bleeding and cannot evaluate pathology arising or presenting afterward.

Takeaway: New postmenopausal bleeding requires diagnostic evaluation; neither an earlier surveillance biopsy nor a thin stripe alone settles the current episode.

Case sources: [1] [9]

1. A. Treat the infection and consider repeat upper endoscopy in 3 to 5 years (Best answer)

   ACG supports treatment of documented H. pylori and consideration of 3-to 5-year follow-up with a gastric or duodenal family history. Other guidance differs.

   Reasoning steps for option A

   1. What action follows the positive gastric H. pylori sample?

      Treat the documented infection even though baseline upper endoscopy found no neoplasia.

   2. Which finding supports considering repeat upper endoscopy in 3 to 5 years under ACG 2015?

      Her mother's gastric cancer supplies the gastric family-history criterion in the risk-selected upper-GI framework.

   3. Does residence in a high-incidence region replace the family-history discriminator?

      No. Her maternal gastric cancer specifically supports considering risk-selected follow-up in the named framework.

2. B. Treat the infection and use the 1-to 2-year colonoscopy interval for the stomach (Why this does not fit)

   Treating infection is appropriate, but the colonoscopy interval is not automatically the upper-endoscopy interval.

   Reasoning steps for option B

   1. Is treating biopsy-proven H. pylori appropriate?

      Yes. The infection is actionable despite a normal neoplasia assessment.

   2. Can the 1-to 2-year colonoscopy interval be copied to upper endoscopy?

      No. Under the specified ACG 2015 risk-selected framework, gastric family history supports considering a 3-to 5-year upper-GI interval.

   3. Which organ-specific interval is being confused?

      The 1-to 2-year schedule belongs to Lynch colonoscopy, not automatically to gastric endoscopy.

3. C. Treat the infection and stop upper endoscopic follow-up after this normal examination (Why this does not fit)

   Normal current mucosa does not erase the family-history context supporting consideration of follow-up.

   Reasoning steps for option C

   1. Does no neoplasia at baseline erase future upper-GI risk considerations?

      No. Her mother's gastric cancer remains relevant to risk-selected follow-up.

   2. What is missing from a treat-and-stop plan?

      It omits consideration of repeat upper endoscopy in 3 to 5 years under the specified ACG 2015 framework.

   3. Why does baseline normality not settle the future surveillance choice?

      No neoplasia today does not remove the maternal gastric cancer history relevant to subsequent endoscopy.

4. D. Defer infection treatment and consider repeat upper endoscopy in 3 to 5 years (Why this does not fit)

   The selected interval is plausible under this framework, but documented H. pylori should be treated rather than deferred.

   Reasoning steps for option D

   1. Is a 3-to 5-year upper-endoscopy discussion reasonable with maternal gastric cancer?

      Yes. That family history supports considering this interval under ACG 2015.

   2. Can treatment of documented H. pylori be deferred simply because endoscopy found no neoplasia?

      No. The positive gastric sampling calls for treatment now, independently of surveillance scheduling.

   3. Are infection management and endoscopy scheduling interchangeable decisions?

      No. The 3-to 5-year endoscopy discussion does not excuse deferring treatment of confirmed H. pylori.

Takeaway: Treat an actionable infection while keeping organ-specific surveillance decisions distinct.

Case sources: [1] [6]

1. A. Renal cortical carcinoma; proceed to percutaneous cortical mass sampling (Why this does not fit)

   The described defect is in the collecting system, not a cortical mass suitable for this proposed target.

   Reasoning steps for option A

   1. Does the renal-pelvis filling defect identify a cortical biopsy target?

      No. The persistent defect lies in the urothelial collecting system, and CT shows no parenchymal mass to sample.

   2. Why would cortical sampling miss the suspected source of hematuria?

      A cortical specimen would not directly assess the renal-pelvis lesion in this MSH2 carrier.

   3. What CT feature contradicts a renal cortical carcinoma target?

      The scan explicitly reports no renal parenchymal mass.

2. B. Bladder urothelial carcinoma; repeat bladder-only cystoscopy to explain the renal finding (Why this does not fit)

   The normal bladder assessment does not settle a persistent renal-pelvis defect; repeating only it misses the relevant compartment.

   Reasoning steps for option B

   1. Does a negative bladder cystoscopy inspect the renal pelvis?

      No. Cystoscopy found no bladder lesion but does not evaluate the persistent upper-tract filling defect.

   2. What is missed by repeating only bladder cystoscopy?

      The abnormality is in the renal pelvis, so bladder-only reassessment would leave its cause unresolved.

   3. Where is the persistent finding relative to the normal bladder exam?

      It is in the renal pelvis, upstream of the bladder inspected by cystoscopy.

3. C. Upper-tract urothelial lesion; pursue diagnostic ureteroscopy and directed assessment (Best answer)

   The collecting-system lesion raises concern for upper-tract urothelial disease. When imaging and voided cytology are insufficient, ureteroscopy can inspect and sample the upper tract; carcinoma is not yet proved.

   Reasoning steps for option C

   1. What diagnosis does the renal-pelvis defect raise in an MSH2 carrier?

      It raises concern for an upper-tract urothelial lesion, although imaging alone does not prove carcinoma.

   2. Why proceed to diagnostic ureteroscopy despite negative voided cytology?

      Voided cytology can miss upper-tract disease; ureteroscopy permits directed inspection and sampling of the persistent pelvic defect.

   3. Does the proposed assessment assume carcinoma is already proved?

      No. Directed ureteroscopic assessment seeks a diagnosis because imaging does not establish one.

4. D. Benign upper-tract bleeding; return to annual urinalysis because cytology is negative (Why this does not fit)

   Negative voided cytology is insufficient reassurance with symptoms and a persistent upper-tract abnormality.

   Reasoning steps for option D

   1. Does negative voided cytology establish benign bleeding here?

      No. Negative cytology cannot exclude an upper-tract lesion in a symptomatic carrier with a persistent renal-pelvis defect.

   2. Why is annual urinalysis insufficient follow-up?

      Visible hematuria and a structural collecting-system finding call for diagnostic assessment rather than routine screening.

   3. Which two findings make routine urinalysis an inadequate response?

      Visible hematuria and a persistent renal-pelvis filling defect require investigation despite negative cytology.

Takeaway: A low-sensitivity screen does not exclude disease in a symptomatic high-risk patient.

Case sources: [1] [7]

1. A. Discuss annual MRI/MRCP and/or endoscopic ultrasound now at an experienced center (Best answer)

   The family-based start is 44, earlier than 50; he is beyond that age and should discuss benefits and uncertainties at an experienced center.

   Reasoning steps for option A

   1. When does surveillance begin given a father diagnosed at 54?

      Ten years before his diagnosis is age 44, earlier than the default age 50; this patient is already 46.

   2. Which surveillance discussion fits the current age and family context?

      Discuss annual MRI/MRCP and/or endoscopic ultrasound now at an experienced center, including benefits and uncertainties.

   3. Which relative meets the family-context requirement?

      His father is on the variant-bearing side and had pancreatic adenocarcinoma at 54.

2. B. Discuss annual MRI/MRCP and/or endoscopic ultrasound starting at 50 (Why this does not fit)

   Age 50 is the default but the family diagnosis at 54 yields an earlier start at 44.

   Reasoning steps for option B

   1. Why does waiting until 50 miss this family-based start?

      The variant-bearing father's diagnosis at 54 moves the proposed start to age 44, six years earlier than 50.

   2. Is age 46 before or after the applicable start?

      He is two years past age 44, so deferring discussion until 50 is inappropriate under the cited framework.

   3. Which arithmetic changes the default age-50 offer?

      Subtracting ten years from 54 yields 44, earlier than 50.

3. C. Discuss annual MRI/MRCP and/or endoscopic ultrasound starting at 54 (Why this does not fit)

   Waiting until the relative's age at diagnosis misses the 10-year offset.

   Reasoning steps for option C

   1. Is the father's age at diagnosis itself the screening start?

      No. The cited rule starts ten years earlier than the affected relative's diagnosis, at 44 rather than 54.

   2. What happens if this 46-year-old waits until 54?

      He delays consideration of surveillance by ten years beyond the family-based starting age.

   3. How many years after the proposed start would age 54 be?

      The calculated start is age 44, so waiting until his father’s diagnosis age of 54 would be ten years late.

4. D. Discuss biennial MRI/MRCP and/or endoscopic ultrasound now (Why this does not fit)

   The cited high-risk approach uses annual rather than biennial surveillance.

   Reasoning steps for option D

   1. Does beginning now make biennial surveillance the cited schedule?

      No. The high-risk approach discussed here uses annual MRI/MRCP and/or endoscopic ultrasound.

   2. Which part of this option fits, and which fails?

      Starting now fits because the calculated start was 44; the proposed two-year interval does not fit the annual approach.

   3. At what age did this patient cross the earlier threshold?

      He crossed the family-based threshold at 44 and is now 46; frequency remains annual.

Takeaway: Confirm the familial context, then calculate the earlier starting age.

Case sources: [1] [6]

1. A. Annual MRI for the younger; urgent diagnostic evaluation of the older (Why this does not fit)

   The symptomatic plan fits, but routine asymptomatic brain MRI is not an established universal Lynch program.

   Reasoning steps for option A

   1. Does an affected uncle establish annual brain MRI for an asymptomatic MSH2 carrier?

      No. A Lynch-associated brain tumor in the family does not establish routine MRI as a universal asymptomatic screening program.

   2. Which half of this paired plan is warranted?

      The older sibling's new focal seizure and persistent weakness warrant urgent diagnostic evaluation, not merely screening.

   3. What does the uncle’s glioblastoma change about the younger sibling’s immediate test indication?

      It raises awareness of Lynch-associated brain tumors but does not create an established universal annual MRI indication in the well sibling.

2. B. Annual MRI for the younger; assessment of the older at the next annual visit (Why this does not fit)

   The asymptomatic screening premise is unsupported, and focal symptoms cannot wait for an annual visit.

   Reasoning steps for option B

   1. Why is annual MRI for the well sibling not the default?

      The younger sibling has no neurologic symptoms or abnormal findings, and routine Lynch brain MRI has no established universal role.

   2. Can the older sibling's focal seizure wait for an annual visit?

      No. New seizure with persistent unilateral weakness calls for urgent diagnostic assessment.

   3. Which ongoing symptom makes an annual review especially unsafe for the older sibling?

      Persistent unilateral weakness after a new focal seizure is an active focal neurologic finding.

3. C. No default MRI for the younger; assessment of the older at the next annual visit (Why this does not fit)

   The asymptomatic approach fits, but new focal seizure and weakness require prompt diagnostic assessment.

   Reasoning steps for option C

   1. Why can the younger sibling forgo default MRI?

      The family association alone does not establish routine imaging benefit in an asymptomatic carrier.

   2. Which finding rules out delaying assessment of the older sibling?

      A new focal seizure accompanied by ongoing unilateral weakness is an active neurologic presentation requiring prompt evaluation.

   3. Would absence of symptoms in the younger sibling justify postponing the older sibling’s workup?

      No. Their needs differ because the older sibling has new focal symptoms requiring urgent evaluation.

4. D. No default MRI for the younger; urgent diagnostic evaluation of the older (Best answer)

   Routine brain MRI is not the asymptomatic default, while new focal findings require urgent diagnostic evaluation.

   Reasoning steps for option D

   1. How do the siblings' current neurologic findings differ?

      The younger has no symptoms or abnormal findings; the older has a new focal seizure and persistent unilateral weakness.

   2. What different actions follow from that contrast?

      Do not institute default annual MRI for the well sibling; urgently evaluate the symptomatic sibling diagnostically.

   3. Is urgent imaging here screening or diagnostic assessment?

      For the symptomatic older sibling, evaluation is diagnostic; the asymptomatic younger sibling has no default annual MRI program.

Takeaway: A cancer association does not automatically establish a useful annual imaging program.

Case sources: [1]

1. A. APC-associated familial adenomatous polyposis (Why this does not fit)

   No diffuse adenomatous polyposis is reported, and sebaceous neoplasms with paired MSH2/MSH6 loss favor a different pathway.

   Reasoning steps for option A

   1. What hallmark of APC-associated polyposis is missing?

      Diffuse adenomatous polyposis is not reported, whereas two sebaceous adenomas and colorectal cancer suggest a different phenotype.

   2. How does paired MSH2/MSH6 loss weigh against APC as the explanation?

      The colon tumor's mismatch-repair protein loss supports a Lynch-pathway evaluation rather than explaining these findings by APC polyposis.

   3. What type of skin lesion is actually documented?

      Two sebaceous adenomas, rather than evidence of an adenomatous colorectal polyposis syndrome.

2. B. A Lynch-associated Muir-Torre phenotype (Best answer)

   Sebaceous neoplasms with a Lynch-associated cancer fit the Muir-Torre phenotype; MSH2/MSH6 loss supports genetics evaluation.

   Reasoning steps for option B

   1. What syndrome links sebaceous adenomas to colorectal cancer?

      Sebaceous neoplasms with a Lynch-associated malignancy characterize the Muir-Torre phenotype.

   2. What does paired MSH2/MSH6 tumor loss establish and not establish?

      It reinforces a Lynch-associated interpretation and warrants genetics evaluation, but tumor staining alone does not prove a germline variant.

   3. Which cancer and skin findings converge on Muir-Torre?

      Prior right-sided colon cancer and two sebaceous adenomas, with MSH2/MSH6 loss in the colon tumor.

3. C. MUTYH-associated adenomatous polyposis (Why this does not fit)

   Adenomatous polyposis is not described; the skin phenotype and MMR pattern are more consistent with a Lynch-associated presentation.

   Reasoning steps for option C

   1. Is adenomatous polyposis described in this patient?

      No. Neither the history nor the tumor description supplies the polyposis pattern expected for MUTYH-associated polyposis.

   2. Which observed findings point elsewhere?

      Sebaceous adenomas plus colon-tumor MSH2/MSH6 loss favor a Lynch-associated Muir-Torre presentation.

   3. Does a right-sided colon cancer alone establish MUTYH polyposis?

      No. Adenomatous polyposis is not described, and the sebaceous lesions together with MSH2/MSH6 loss favor a Lynch-associated explanation.

4. D. STK11-associated Peutz-Jeghers syndrome (Why this does not fit)

   The reported lesions are sebaceous adenomas, not the characteristic mucocutaneous pigmentation with hamartomatous polyps.

   Reasoning steps for option D

   1. Are the skin lesions characteristic Peutz-Jeghers pigmentation?

      No. They are sebaceous adenomas rather than characteristic mucocutaneous pigmentation.

   2. What gastrointestinal pattern expected with STK11 is not supplied?

      Hamartomatous polyps are not described; the colon tumor instead shows paired MSH2/MSH6 loss.

   3. How does the paired protein loss discriminate from STK11 disease?

      MSH2/MSH6 loss supports mismatch-repair pathway evaluation, whereas characteristic pigmentation and hamartomatous polyps are not reported.

Takeaway: Use extracolonic findings to reinforce, not replace, molecular evaluation.

Case sources: [1]

1. A. Start 600 mg aspirin now and continue the established colonoscopy schedule (Why this does not fit)

   Maintaining colonoscopy is correct, but trial dosing is not a safe automatic prescription in someone with anticoagulation and prior ulcer bleeding.

   Reasoning steps for option A

   1. Does CAPP2's 600 mg trial dose mandate an immediate prescription?

      No. Concurrent anticoagulation and previous ulcer bleeding create substantial individual bleeding concerns despite trial efficacy.

   2. Does retaining colonoscopy resolve this option's safety problem?

      No. Continuing surveillance is appropriate, but aspirin risk still needs assessment before starting 600 mg.

   3. Which co-medication raises bleeding concerns with 600 mg aspirin?

      His anticoagulant for atrial fibrillation adds bleeding risk to his history of ulcer bleeding.

2. B. Start low-dose aspirin now and continue the established colonoscopy schedule (Why this does not fit)

   A lower dose does not eliminate the need to evaluate the stated bleeding risks before starting.

   Reasoning steps for option B

   1. Does a low dose remove the need for bleeding-risk assessment?

      No. Anticoagulation and prior ulcer bleeding remain relevant even if the contemplated aspirin dose is lower.

   2. What should happen before starting aspirin in this patient?

      Assess individual bleeding risk and the benefit-harm balance rather than prescribe immediately on the basis of dose alone.

   3. Which prior event remains relevant even with low-dose aspirin?

      A previous ulcer bleed is still a material harm consideration before adding aspirin to anticoagulation.

3. C. Continue colonoscopy; assess bleeding risk before prescribing aspirin (Best answer)

   Delayed trial benefit supports discussion, but anticoagulation and prior ulcer bleeding materially affect the individual balance.

   Reasoning steps for option C

   1. What did CAPP2 support, and what remains patient-specific?

      Long-term colorectal prevention benefit supports discussing aspirin; anticoagulation and past ulcer bleeding make net benefit and regimen individual decisions.

   2. Should aspirin deliberation interrupt his colonoscopy schedule?

      No. Continue established colonoscopy while assessing bleeding risk before any aspirin prescription.

   3. What trial conclusion remains applicable during individualized prescribing?

      CAPP2 supports delayed colorectal prevention benefit, but it does not remove the need to weigh bleeding harms.

4. D. Continue colonoscopy; permanently exclude aspirin because it lacks efficacy (Why this does not fit)

   CAPP2 supports efficacy over long follow-up; the uncertainty here is individual net benefit and regimen, not an absence of colorectal benefit.

   Reasoning steps for option D

   1. Does CAPP2 show aspirin has no colorectal preventive efficacy?

      No. Its long-term results support benefit, so a categorical efficacy-based exclusion misstates the evidence.

   2. What justifies caution without a permanent efficacy-based ban?

      Anticoagulation and previous ulcer bleeding require individualized harm assessment, while colonoscopy continues.

   3. Is the obstacle lack of efficacy or individual safety?

      Individual safety: CAPP2 supports efficacy, while anticoagulation and past ulcer bleeding complicate prescribing.

Takeaway: Prevention evidence must be integrated with competing harms, not used to cancel proven surveillance.

Case sources: [1] [3]

1. A. About 4 points crude absolute difference; assess his bleeding risk before choosing a regimen (Best answer)

   The proportions are about 9.4% and 13.4%, a crude difference near 4 points. A relative hazard reduction is not a personal absolute benefit; anticoagulation and prior major bleeding require individualized assessment.

   Reasoning steps for option A

   1. What crude absolute difference follows from 40/427 versus 58/434?

      The proportions are about 9.4% and 13.4%, giving roughly 4 percentage points, not 35 points.

   2. Why not prescribe the trial dose automatically despite that difference?

      The hazard ratio is a group relative measure; his anticoagulation and major ulcer bleed require individualized harm assessment while colonoscopy continues.

   3. What does the hazard ratio of 0.65 measure instead of personal absolute benefit?

      It is a relative time-to-event hazard estimate, not a 35-percentage-point change in this patient’s risk.

2. B. About 4 points crude absolute difference; initiate the trial dose without further harm assessment (Why this does not fit)

   The calculation is correct, but group benefit does not establish net benefit for this higher-bleeding-risk individual or justify automatic trial-dose prescribing.

   Reasoning steps for option B

   1. Is the proposed four-point calculation accurate?

      Yes. The trial proportions differ by approximately four crude percentage points.

   2. What clinical fact defeats immediate trial-dose prescribing?

      His anticoagulant use and prior major ulcer bleed mean group efficacy does not establish his personal net benefit.

   3. Which two patient-specific facts remain after the correct arithmetic?

      He takes anticoagulation after venous thromboembolism and has had a major ulcer bleed.

3. C. About 35 points absolute difference; assess his bleeding risk before choosing a regimen (Why this does not fit)

   Harm assessment is appropriate, but 0.65 denotes a relative hazard measure, not a 35-point absolute difference.

   Reasoning steps for option C

   1. Does a hazard ratio of 0.65 mean a 35-point absolute benefit?

      No. It expresses a relative time-to-event hazard comparison, while observed event proportions differ by about four percentage points.

   2. Which part of this plan remains appropriate?

      Assessing his bleeding risk before selecting an aspirin regimen is appropriate given anticoagulation and major ulcer bleeding.

   3. How is the observed absolute difference obtained?

      Subtract about 9.4% on aspirin from about 13.4% on placebo to obtain roughly 4 percentage points.

4. D. About 35 points absolute difference; initiate the trial dose without further harm assessment (Why this does not fit)

   Both the effect-size interpretation and automatic prescribing inference are unsupported.

   Reasoning steps for option D

   1. What is wrong with the claimed 35-point difference?

      40/427 and 58/434 yield roughly 9.4% and 13.4%; a hazard ratio of 0.65 is not a 35-point absolute difference.

   2. Why is immediate trial-dose initiation additionally unsupported?

      Anticoagulation after venous thromboembolism and a major ulcer bleed require a personal bleeding-risk assessment first.

   3. Does retaining colonoscopy fix either incorrect inference?

      No. Continued colonoscopy is appropriate but cannot turn a relative hazard into a 35-point absolute benefit or negate bleeding risk.

Takeaway: Distinguish observed absolute risk differences from time-to-event relative measures.

Case sources: [3]

1. A. Use lifelong MSH2-carrier intervals solely because her brother carries the variant (Why this does not fit)

   An adequate true negative does not establish the familial MSH2 predisposition in her.

   Reasoning steps for option A

   1. What does her adequately negative familial MSH2 test establish?

      The known variant in her brother was detectable by this assay but is absent in her, so it does not assign her MSH2-carrier status.

   2. Why are carrier-specific intervals not justified solely by her brother's result?

      His variant is not hers on this informative test; her own colorectal cancer supplies a separate surveillance indication.

   3. What confirms this is an informative true negative for the family variant?

      The laboratory confirms that the brother’s pathogenic MSH2 variant was detectable by her targeted assay.

2. B. Return directly to population screening because the familial test is negative (Why this does not fit)

   The negative familial test does not erase her personal history of colorectal cancer and retained colon.

   Reasoning steps for option B

   1. Does a true negative familial test erase a previous colon cancer?

      No. It addresses inherited familial-variant status, not the follow-up need after curative segmental colectomy.

   2. Why is population screening alone too little?

      She retains colon and has a personal colorectal cancer history requiring post-cancer surveillance.

   3. What anatomic history preserves her need for surveillance?

      She underwent segmental rather than total colectomy and retains colon after colorectal cancer.

3. C. Suspend endoscopy until a second germline panel identifies another variant (Why this does not fit)

   Her cancer history already requires follow-up; endoscopy should not depend on identifying another inherited cause.

   Reasoning steps for option C

   1. Must another germline variant be found before endoscopy resumes?

      No. Her prior colorectal cancer already establishes the follow-up indication independently of further germline testing.

   2. What do the completed tumor and broader genetics assessments change?

      They reveal no additional suspicious finding, but do not justify suspending post-cancer endoscopic surveillance.

   3. Why is a second panel not a prerequisite here?

      Broader genetics and tumor assessment are already completed without another suspicious finding, and cancer follow-up is independent of a molecular explanation.

4. D. Use appropriate post-cancer surveillance without assigning MSH2-carrier status (Best answer)

   She is negative for the known familial cause but still has an independent post-cancer indication for surveillance. Other concerning findings would deserve separate assessment.

   Reasoning steps for option D

   1. How does her negative result differ from an uninformative negative panel?

      It specifically excludes her brother's detectable pathogenic MSH2 variant on an adequate targeted test.

   2. Which indication still calls for colonoscopy?

      Her personal colorectal cancer treated by segmental colectomy requires appropriate post-cancer surveillance without labeling her an MSH2 carrier.

   3. Does the familial result exclude every reason for follow-up?

      No. It excludes the known inherited MSH2 variant, not the post-cancer surveillance indication.

Takeaway: An informative familial negative is different from an unexplained negative panel.

Case sources: [1]

1. A. A:25% chance for each child;B:50% chance for each child (Why this does not fit)

   A has an autosomal dominant constitutional predisposition, not a 25% transmission rule; B's demonstrated events are acquired.

   Reasoning steps for option A

   1. What inheritance probability applies to A's blood-confirmed heterozygous MSH6 variant?

      Each child has a 50% chance of inheriting that constitutional variant, not 25%.

   2. Can B's tumor-confined MSH2 alterations be assigned 50% transmission?

      No. Both explanatory events are absent from matched normal tissue, and adequate germline testing is negative.

   3. Does a 25% figure describe transmission from a single heterozygous autosomal dominant parent?

      No. Each child independently has a one-in-two chance of inheriting A’s identified MSH6 variant.

2. B. A:50% chance for each child;B:no transmissible variant established (Best answer)

   A's constitutional heterozygous variant has a 1 in 2 transmission probability. B's tumor events do not establish a familial variant; neither tumor phenotype makes cancer inevitable in children.

   Reasoning steps for option B

   1. Why does A have a one-in-two transmission probability?

      A pathogenic heterozygous MSH6 variant confirmed in blood is constitutional and follows autosomal dominant transmission.

   2. What has B's matched tumor-normal testing established for offspring?

      The MSH2 events are tumor-only, so no transmissible variant is established; inheriting a predisposition is not the same as inevitable cancer.

   3. What makes B’s alterations somatic rather than demonstrated constitutional variants?

      Both MSH2 events are absent from matched normal tissue, alongside adequate negative germline testing.

3. C. A:50% chance for each child;B:50% chance for each child (Why this does not fit)

   The probability for A is correct, but the same dMMR phenotype does not make B's tumor-only events constitutional.

   Reasoning steps for option C

   1. Which half of the two 50% claims is supported?

      A's blood-confirmed heterozygous MSH6 variant has a 50% chance of transmission to each child.

   2. Why does B's dMMR tumor not establish the same risk?

      B's two MSH2 events are absent from matched normal tissue, with adequate negative germline testing; tumor phenotype is not a constitutional result.

   3. Does dMMR alone imply a 50% risk of inheriting cancer?

      No. A’s 50% applies to variant transmission, not certainty of cancer; B has no established inherited variant.

4. D. A:no transmissible variant established;B:no transmissible variant established (Why this does not fit)

   A's blood result establishes a constitutional variant even though B's does not.

   Reasoning steps for option D

   1. Is A's pathogenic MSH6 variant restricted to the tumor?

      No. Its confirmation in blood demonstrates a constitutional variant capable of transmission.

   2. Which adult actually lacks an established transmissible variant?

      B does: both identified MSH2 events are tumor-specific and adequate germline testing is negative.

   3. Which sample distinguishes A from B for reproductive counseling?

      A’s blood contains the pathogenic MSH6 variant, whereas B’s identified MSH2 events are absent from normal tissue.

Takeaway: Transmission of predisposition and development of cancer are distinct events.

Case sources: [1]

1. A. End inherited evaluation because tumor methylation fully explains both primary cancers (Why this does not fit)

   Methylation favors a sporadic mechanism in many settings but is not sufficient reassurance with this striking early multiple-primary history.

   Reasoning steps for option A

   1. Does tumor MLH1 methylation explain away both exceptionally early primaries?

      No. It often favors acquired silencing but does not settle constitutional risk in a patient with endometrial cancer at 25 and colorectal cancer at 28.

   2. Which pedigree detail prevents ending inherited evaluation?

      Her mother's colorectal cancer at 34 reinforces suspicion despite the tumor methylation result.

   3. What does MLH1/PMS2 loss plus tumor methylation localize without proving?

      It points to MLH1 silencing in this tumor, but does not prove both primary cancers have exclusively sporadic origins.

2. B. Limit inherited evaluation to MLH1 coding sequence and ignore methylation outside the tumor (Why this does not fit)

   Coding sequence analysis alone would not address the constitutional methylation mechanism suggested by this unusually early presentation.

   Reasoning steps for option B

   1. Why is MLH1 coding analysis alone incomplete?

      A coding assay would not detect constitutional MLH1 methylation, a rare mechanism relevant to this unusually early presentation.

   2. What history supports assessment beyond coding sequence?

      Two primary cancers by age 28 and maternal colorectal cancer at 34 sustain inherited-risk concern despite tumor methylation.

   3. Why consider methylation beyond the colorectal tumor?

      Rare constitutional MLH1 methylation would not be resolved by checking only the coding sequence of MLH1.

3. C. Evaluate inherited causes, including constitutional MLH1 methylation (Best answer)

   Very early cancers and a strong pedigree justify further assessment despite tumor methylation, including constitutional MLH1 methylation where appropriate.

   Reasoning steps for option C

   1. What does methylation in the tumor usually suggest?

      It often supports acquired MLH1 silencing, but is not conclusive evidence against inherited causes in this extreme clinical context.

   2. Which additional constitutional mechanism should evaluation consider?

      Constitutional MLH1 methylation is a rare possibility alongside other inherited causes given multiple very early primaries and the maternal history.

   3. Which ages make this unlike a routine late-onset methylated tumor?

      Endometrial cancer occurred at 25, colorectal cancer at 28, and her mother had colorectal cancer at 34.

4. D. Use tumor-only MMR sequencing as the sole inherited-risk assessment (Why this does not fit)

   Tumor sequencing may help, but tumor-only results cannot settle whether a constitutional cause explains the striking personal and family history.

   Reasoning steps for option D

   1. Can tumor-only sequencing distinguish a constitutional cause here?

      No. Findings restricted to tumor cannot by themselves establish or exclude an alteration present outside the tumor.

   2. Why does this history demand more than tumor-only assessment?

      Endometrial cancer at 25, colorectal cancer at 28 and maternal colorectal cancer at 34 sustain suspicion requiring constitutional evaluation.

   3. What compartment must be evaluated to test constitutional suspicion?

      Tissue outside the tumor is needed to investigate a constitutional mechanism such as MLH1 methylation.

Takeaway: Clinical context can prevent an overly absolute interpretation of a sporadic-pathway marker.

Case sources: [1]

1. A. Assess biomarker-directed treatment in both; target the known germline variant in the first family (Best answer)

   Tumor biology can inform systemic treatment in both; only the established constitutional variant provides a specific familial cascade target here.

   Reasoning steps for option A

   1. Do the two tumors differ in MSI-high/dMMR treatment relevance?

      No. Both metastatic tumors share the biomarker biology that can inform systemic treatment assessment regardless of its inherited or acquired origin.

   2. Which family has a defined cascade-test target?

      The first patient's confirmed germline MSH2 variant provides a specific target; the second patient's double-somatic events do not.

   3. Does double-somatic origin negate MSI-high status?

      No. The second metastatic tumor remains MSI-high and dMMR despite its acquired cause.

2. B. Assess biomarker-directed treatment only in the germline carrier; test that carrier's relatives (Why this does not fit)

   Familial evaluation is appropriate for the constitutional variant, but acquired dMMR can also inform systemic treatment.

   Reasoning steps for option B

   1. Does double-somatic dMMR eliminate biomarker-directed treatment consideration?

      No. The second patient's metastatic cancer remains MSI-high and dMMR, which can inform systemic therapy even without germline MSH2.

   2. Which part of this option is valid?

      Relatives of the first patient can be offered targeted assessment for the confirmed constitutional MSH2 variant.

   3. What is shared between these patients despite different inherited status?

      Their metastatic colorectal cancers are both MSI-high and dMMR, so both merit biomarker-directed treatment assessment.

3. C. Assess biomarker-directed treatment in both; target tumor-only variants in both families (Why this does not fit)

   The shared treatment relevance is correct; tumor-only variants in the acquired case are not established familial cascade targets.

   Reasoning steps for option C

   1. Why can both patients be assessed for biomarker-directed treatment?

      Both metastatic colorectal tumors are MSI-high and dMMR, despite distinct origins of repair deficiency.

   2. Why not use the acquired patient's tumor-only variants for family cascade testing?

      Well-supported double-somatic alterations are not established constitutional variants in relatives.

   3. Which result specifically supports family cascade testing?

      The first patient’s confirmed germline MSH2 variant, not the second patient’s tumor-only events.

4. D. Assess biomarker-directed treatment only in the acquired case; omit familial testing in both (Why this does not fit)

   Inherited dMMR can also inform treatment, and the identified constitutional variant has implications for relatives.

   Reasoning steps for option D

   1. Why is treatment assessment not limited to the acquired case?

      The germline carrier's metastatic tumor is also MSI-high and dMMR, making its biomarker relevant to systemic treatment.

   2. Which familial action would omission miss?

      The first patient's confirmed germline MSH2 variant is a defined cascade-testing target for relatives, unlike the double-somatic case.

   3. What separate decisions must tumor board avoid conflating?

      MSI-high/dMMR treatment relevance applies to both, but targeted familial testing follows the confirmed germline MSH2 result only.

Takeaway: Keep biomarker-directed treatment, anatomic stage and inherited counseling separate.

Case sources: [1]